Page 5 - Ongoing Phase News Today

— Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer to be presented at the 2023 American Society of Clinical Oncology annual meeting... | May 9, 2023

Continued progress across pipeline, including encouraging BT8009 Phase I dose escalation results presented in Q1'23 Entered into a strategic collaboration with Novartis and expanded separate collaboration

Continued to Advance Monotherapy Dose Escalation Stage of Ongoing Phase 1/2 MYCHELANGELO™ I Study; Preliminary Data Anticipated in 2023Announced Clinical Supply Agreement with Roche to Evaluate... | May 4, 2023

  A major obstacle to the treatment of glioblastoma, a deadly brain tumor, is the inability of the most potent chemotherapy to cross the blood-brain barrier to reach aggressive brain tumors. But now, scientists at Northwestern Medicine are using a novel ultrasound device that can be implanted in the skull to open the blood-brain barrier […]

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to... | April 12, 2023

Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023Announced preclinical data for differentiated chimeric antigen receptor (CAR) and chimeric adaptor (CAd) progr...

-   89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up -   Rapid and deep responses seen including...

-Ongoing Phase 2 trial in collaboration with Columbia University demonstrated that sotigalimab (sotiga) in combination with doxorubicin achieved a median...

As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1 study during ASH Annual MeetingCompany to host ADI-001 webcast event on December 11, 2022 at 9:00 a.m. ETOn track to initiate a potentially pivotal program f...

WALTHAM, Mass., Nov. 04, 2022 -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am ET, to correct... | November 4, 2022